Fig. 5

Pharmacological inhibition of PRP-induced proliferation through JNK and p38 pathways. After incubation in serum-free DMEM for 6 h, cells were treated with inhibitors at the designated concentrations for 48 h. Cell proliferation assessed with Cell Counting Kit-8. Cells treated with ERK1/2 inhibitor (PD98059, 20 μM), PI3K/Akt inhibitor (LY294002, 10 μM), JNK inhibitor (SP600125, 20 μM), or p38 inhibitor (SB203580, 10 μM) (n = 4). *P < 0.01 compared with no inhibitor. ERK extracellular signal-regulated kinase, JNK c-Jun N-terminal kinase, Akt protein kinase B, PRP platelet-rich plasma